Immunotherapy of established tumors using bone marrow transplantation with antigen gene-modified hematopoietic stem cells

Yan Cui, Erin Kelleher, Erin Straley, Ephraim Fuchs, Kevin Gorski, Hyam Levitsky, Ivan Borrello, Curt I. Civin, Stephen P. Schoenberger, Linzhao Cheng, Drew M. Pardoll, Katharine A. Whartenby

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

A major focus of cancer immunotherapy is to develop strategies to induce T-cell responses through presentation of tumor antigens by dendritic cells (DCs). Current vaccines are limited in their ability to efficiently transfer antigens to DCs in vivo. Ex vivo - generated DCs can be efficiently loaded with antigen but after reinjection, few DCs traffic to secondary lymphoid organs, the critical sites for antigen presentation. To enhance efficiency and durability of antigen presentation by DCs, we transduced hematopoietic stem-progenitor cells (HSCs) with a model tumor antigen and then transplanted the gene-modified cells into irradiated recipient mice, which resulted in efficient expression of the transgene in a large proportion of donor derived DCs in lymphoid organs. The combination of bone marrow transplantion (BMT) using transduced HSCs, systemic agents that generate and activate DCs, and mature T-cell infusion resulted in substantial expansion and activation of antigen-specific T cells. This tripartite strategy provided potent antigen-specific immunotherapy for an aggressive established tumor.

Original languageEnglish (US)
Pages (from-to)952-958
Number of pages7
JournalNature Medicine
Volume9
Issue number7
DOIs
StatePublished - Jul 1 2003

Fingerprint

Histocompatibility Antigens
Hematopoietic Stem Cells
Stem cells
Bone Marrow Transplantation
Immunotherapy
Dendritic Cells
Tumors
Bone
Genes
Antigens
T-cells
Neoplasms
Antigen Presentation
Neoplasm Antigens
CD27 Antigens
T-Lymphocytes
Transgenes
Durability
Vaccines
Bone Marrow

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Immunotherapy of established tumors using bone marrow transplantation with antigen gene-modified hematopoietic stem cells. / Cui, Yan; Kelleher, Erin; Straley, Erin; Fuchs, Ephraim; Gorski, Kevin; Levitsky, Hyam; Borrello, Ivan; Civin, Curt I.; Schoenberger, Stephen P.; Cheng, Linzhao; Pardoll, Drew M.; Whartenby, Katharine A.

In: Nature Medicine, Vol. 9, No. 7, 01.07.2003, p. 952-958.

Research output: Contribution to journalArticle

Cui, Y, Kelleher, E, Straley, E, Fuchs, E, Gorski, K, Levitsky, H, Borrello, I, Civin, CI, Schoenberger, SP, Cheng, L, Pardoll, DM & Whartenby, KA 2003, 'Immunotherapy of established tumors using bone marrow transplantation with antigen gene-modified hematopoietic stem cells', Nature Medicine, vol. 9, no. 7, pp. 952-958. https://doi.org/10.1038/nm882
Cui, Yan ; Kelleher, Erin ; Straley, Erin ; Fuchs, Ephraim ; Gorski, Kevin ; Levitsky, Hyam ; Borrello, Ivan ; Civin, Curt I. ; Schoenberger, Stephen P. ; Cheng, Linzhao ; Pardoll, Drew M. ; Whartenby, Katharine A. / Immunotherapy of established tumors using bone marrow transplantation with antigen gene-modified hematopoietic stem cells. In: Nature Medicine. 2003 ; Vol. 9, No. 7. pp. 952-958.
@article{d33f07070d5742ccad327a664f751a2e,
title = "Immunotherapy of established tumors using bone marrow transplantation with antigen gene-modified hematopoietic stem cells",
abstract = "A major focus of cancer immunotherapy is to develop strategies to induce T-cell responses through presentation of tumor antigens by dendritic cells (DCs). Current vaccines are limited in their ability to efficiently transfer antigens to DCs in vivo. Ex vivo - generated DCs can be efficiently loaded with antigen but after reinjection, few DCs traffic to secondary lymphoid organs, the critical sites for antigen presentation. To enhance efficiency and durability of antigen presentation by DCs, we transduced hematopoietic stem-progenitor cells (HSCs) with a model tumor antigen and then transplanted the gene-modified cells into irradiated recipient mice, which resulted in efficient expression of the transgene in a large proportion of donor derived DCs in lymphoid organs. The combination of bone marrow transplantion (BMT) using transduced HSCs, systemic agents that generate and activate DCs, and mature T-cell infusion resulted in substantial expansion and activation of antigen-specific T cells. This tripartite strategy provided potent antigen-specific immunotherapy for an aggressive established tumor.",
author = "Yan Cui and Erin Kelleher and Erin Straley and Ephraim Fuchs and Kevin Gorski and Hyam Levitsky and Ivan Borrello and Civin, {Curt I.} and Schoenberger, {Stephen P.} and Linzhao Cheng and Pardoll, {Drew M.} and Whartenby, {Katharine A.}",
year = "2003",
month = "7",
day = "1",
doi = "10.1038/nm882",
language = "English (US)",
volume = "9",
pages = "952--958",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Immunotherapy of established tumors using bone marrow transplantation with antigen gene-modified hematopoietic stem cells

AU - Cui, Yan

AU - Kelleher, Erin

AU - Straley, Erin

AU - Fuchs, Ephraim

AU - Gorski, Kevin

AU - Levitsky, Hyam

AU - Borrello, Ivan

AU - Civin, Curt I.

AU - Schoenberger, Stephen P.

AU - Cheng, Linzhao

AU - Pardoll, Drew M.

AU - Whartenby, Katharine A.

PY - 2003/7/1

Y1 - 2003/7/1

N2 - A major focus of cancer immunotherapy is to develop strategies to induce T-cell responses through presentation of tumor antigens by dendritic cells (DCs). Current vaccines are limited in their ability to efficiently transfer antigens to DCs in vivo. Ex vivo - generated DCs can be efficiently loaded with antigen but after reinjection, few DCs traffic to secondary lymphoid organs, the critical sites for antigen presentation. To enhance efficiency and durability of antigen presentation by DCs, we transduced hematopoietic stem-progenitor cells (HSCs) with a model tumor antigen and then transplanted the gene-modified cells into irradiated recipient mice, which resulted in efficient expression of the transgene in a large proportion of donor derived DCs in lymphoid organs. The combination of bone marrow transplantion (BMT) using transduced HSCs, systemic agents that generate and activate DCs, and mature T-cell infusion resulted in substantial expansion and activation of antigen-specific T cells. This tripartite strategy provided potent antigen-specific immunotherapy for an aggressive established tumor.

AB - A major focus of cancer immunotherapy is to develop strategies to induce T-cell responses through presentation of tumor antigens by dendritic cells (DCs). Current vaccines are limited in their ability to efficiently transfer antigens to DCs in vivo. Ex vivo - generated DCs can be efficiently loaded with antigen but after reinjection, few DCs traffic to secondary lymphoid organs, the critical sites for antigen presentation. To enhance efficiency and durability of antigen presentation by DCs, we transduced hematopoietic stem-progenitor cells (HSCs) with a model tumor antigen and then transplanted the gene-modified cells into irradiated recipient mice, which resulted in efficient expression of the transgene in a large proportion of donor derived DCs in lymphoid organs. The combination of bone marrow transplantion (BMT) using transduced HSCs, systemic agents that generate and activate DCs, and mature T-cell infusion resulted in substantial expansion and activation of antigen-specific T cells. This tripartite strategy provided potent antigen-specific immunotherapy for an aggressive established tumor.

UR - http://www.scopus.com/inward/record.url?scp=0038379169&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038379169&partnerID=8YFLogxK

U2 - 10.1038/nm882

DO - 10.1038/nm882

M3 - Article

C2 - 12778137

AN - SCOPUS:0038379169

VL - 9

SP - 952

EP - 958

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 7

ER -